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Abstract
Background: In 2012, the international nephrology organization Kidney Disease Improving Global Outcomes
(KDIGO) released recommendations for nephrology referral for chronic kidney disease (CKD) patients. The feasibility
of adhering to these recommendations is unknown.
Methods: We conducted a retrospective analysis of the primary care population at Brigham and Women’s Hospital
(BWH). We translated referral recommendations based upon serum creatinine, estimated glomerular filtration rate
(eGFR), and albuminuria into a set of computable criteria in order to project referral volume if the KDIGO referral
recommendations were to be implemented. Using electronic health record data, we evaluated each patient using
the computable criteria at the times that the patient made clinic visits in 2013. We then compared the projected
referral volume with baseline nephrology clinic volume.
Results: Out of 56,461 primary care patients at BWH, we identified 5593 (9.9%) who had CKD based on albuminuria
or estimated GFR. Referring patients identified by the computable criteria would have resulted in 2240 additional
referrals to nephrology. In 2013, this would represent a 38.0% (2240/5892) increase in total nephrology patient
volume and 67.3% (2240/3326) increase in new referral volume.
Conclusions: This is the first study to examine the projected impact of implementing the 2012 KDIGO referral
recommendations. Given the large increase in the number of referrals, this study is suggestive that implementing
the KDIGO referral guidelines may not be feasible under current practice models due to a supply-demand
mismatch. We need to consider new strategies on how to deliver optimal care to CKD patients using the available
workforce in the U.S. health care system.
Background
Several studies have identified benefits of early nephrology
referral among CKD patients, including reduced mortality
at 3 months to 5 years of follow-up [1, 2], reduced costs [3],
reduced length of stay among hospitalized patients [1, 4],
increased quality of life [2], and earlier placement of pre-
ferred dialysis access [1]. Early referral to a nephrologist has
been recognized as a national priority. One objective of the
U.S. Office of Disease Prevention and Health Promotion’s
Healthy People 2020 initiative is to increase the proportion
of chronic kidney disease patients receiving care from a
nephrologist at least 12 months before the start of renal
replacement therapy [5]. Based on mounting evidence fa-
voring early referral, the international nephrology
organization Kidney Disease Improving Global Outcomes
(KDIGO) defined indications for nephrology referral as part
of a broader guideline for CKD management in 2012 [6].
KDIGO defined indications for referral of CKD patients
who are most likely to benefit from diagnostic work-up,
close monitoring, or planning for renal replacement
therapy through consultation with a nephrologist [4, 7, 8].
Referral to a nephrologist for this group of patients was
considered a level 1B recommendation, denoting that it is
based on “moderate” quality evidence. The indications for
referral include acute kidney injury, progressive or
advanced CKD, albuminuria, urinary red cell casts, refrac-
tory hypertension, potassium abnormalities, recurrent
nephrolithiasis, and hereditary kidney disease.
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The prevalence of CKD is over 10% [9] and the nephrol-
ogy workforce is limited. While there are an estimated
246,500 primary care physicians currently practicing in the
United States [10], the estimated practicing nephrology
workforce is just over 9000 [11]. Referring all patients iden-
tified by the KDIGO CKD guidelines may not be feasible
due to a mismatch in nephrologist supply and demand.
We sought to estimate the number of referrals that
would be generated by adhering to the KDIGO referral
recommendations in a primary care population among in-
dividuals with pre-existing CKD, and then compare this
estimate against the baseline referral volume to assess the
feasibility of adhering to these recommendations.
Methods
Participants
We first identified all patients seen in the Brigham and
Women’s Hospital (BWH) primary care network of 15
practices from January 1 to December 31 of 2013. We
then selected patients who had at least one visit dating
back to 2009 with a BWH primary care to eliminate pa-
tients seen at BWH solely on a referral basis. Since KDI-
GO’s referral recommendations only apply to individuals
with CKD, we then selected patients with CKD, defined as
two estimated glomerular filtration rates (eGFRs) < 60 ml/
min/1.73m2 or urine microalbumin/creatinine ratios
≥30 μg/mg at least 3 months apart at any time between
2007 and 2012. eGFR was calculated using the CKD-EPI
formula [9].
Brigham and Women’s Hospital is a 793-bed tertiary
care hospital that belongs to the Partners Healthcare
system, the largest healthcare provider in Massachusetts.
The BWH primary care network includes hospital-based
practices, community-based practices, and two federally
qualified health centers.
Data source
We used retrospective patient data from the Partners
Research Patient Data Registry (RPDR), which is the
centralized clinical data warehouse for research at Part-
ners Healthcare. From this source, we obtained two
datasets. The first consisted of all patients seen in one of
the 15 BWH primary care practices in 2013. The second
consisted of all patients seen by a BWH nephrologist be-
tween 2005 and 2015. The first dataset was used to de-
termine which patients met criteria for nephrology
referral. The second dataset was used to measure neph-
rology outpatient practice volume, including patients re-
ferred to BWH nephrologists from non-BWH providers.
Study design
We conducted a retrospective analysis to determine how
adherence to the KDIGO referral recommendations
would impact the number of nephrology referrals. Using
the referral recommendations as a guide, we constructed
a series of 12 computable criteria for which KDIGO
recommends referral, focused on the following general
indications: acute kidney injury (AKI), albuminuria, early
CKD progression, late stable CKD, late CKD progres-
sion, and high annual decline in GFR (Table 1).
We focused on recommendations based upon serum
creatinine, eGFR, and albuminuria because chronic kidney
disease and acute kidney injury have well-accepted defini-
tions in the nephrology community [12, 13] and can be
readily computed using electronic health record (EHR)
data. We did not include diagnoses such as hereditary kid-
ney disease in the construction of the referral scenarios
because electronic problem list documentation is known
to be sparse [14] and billing codes may be inaccurate [15].
We then evaluated whether these patients met one of
the KDIGO indications for referral at any of their out-
patient visits in 2013. We only used information that
would have been available to clinical providers on the date
that each visit occurred. The definition of baseline eGFR
or urine microalbumin/creatinine ratio varies among the
12 scenarios (Table 1) because the timing of the baseline
value may appropriately differ in the setting of progressive
chronic kidney disease and acute injury. We updated the
baseline values at each visit based the definitions within
each scenario. Patients were considered candidates for re-
ferral if they met criteria for referral during any of their
visits in 2013. For patients to be considered “projected
new referrals,” they had to meet both of these criteria: 1)
qualify for any of the computable indications for nephrol-
ogy referral during any of their outpatient clinical visits in
2013; and 2) have no outpatient or inpatient visits with a
nephrologist in 2013.
To measure the impact of referral on current practice,
we first determined baseline nephrology clinic volume at
BWH in 2013. We then compared the number of patients
who met criteria for each of the scenarios to the number
who had either an outpatient visit or inpatient referral
with a nephrologist in 2013 to determine the number of
“projected new referrals” under the assumption of perfect
guideline adherence.
Approval for this study was granted by the institu-
tional review board at Partners Healthcare, and the need
for informed consent was waived.
Results
Out of 56,461 BWH primary care patients, we identified
5593 (9.9%) with pre-existing CKD. As compared to all
primary care patients, the patients with CKD were older,
less likely to be female, with a lower baseline eGFR and
greater degree of albuminuria (Table 2).
For the 5593 patients with pre-existing CKD, we
evaluated 37,056 outpatient visits in 2013 and found
that 2851 patients met criteria for at least one of the
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12 computable scenarios for nephrology referral. Of
these patients with CKD, only 21.4% (611/2851) were
seen by a BWH nephrologist in 2013, while we classi-
fied the remaining 2240 as “projected new referrals”
to nephrology (Fig. 1). In comparison to the CKD
patients who saw a nephrologist in 2013, the pro-
jected new referrals were older, more likely to be
female, more likely to be Caucasian and less likely to
be black, and had a higher baseline eGFR and lesser
degree of albuminuria (Table 3).
Table 2 Baseline characteristics of primary care population and CKD population
Characteristic Primary care population All patients with CKD P-value
No. of patients 56,461 5593 –
Age in years, mean (SD) 54.7 (15.5) 70.7 (12.4) <0.001*






































Urine microalbumin to creatinine ratio, μg/mg, median (IQR) 0 (IQR [0,35]) 32.9 (IQR [0,131.1]) < 0.001***
Baseline eGFR is calculated based on the first available creatinine result in 2013
*Welch’s two-sample T-test
**Χ2 test
***Wilcoxon rank sum test
Table 1 Computable criteria for indications for nephrology referral in the KDIGO 2012 CKD guidelines
Diagnosis Scenario Criteria used to identify patients
Acute Kidney Injury 1 Creatinine rises by 0.3 mg/dL on most recent lab as compared to prior lab checks within last 48 h
2 Creatinine has risen by at least 1.5 times within past 7 days
3 Estimated GFR is 50% lower as compared to the baseline eGFR, with baseline
eGFR defined as the highest eGFR from the past 6 months (“abrupt sustained fall in GFR”)
Late Stable Chronic Kidney Disease 4 Recent eGFR and eGFR prior to 3 months ago are both <30 ml/min/1.73m2
5 Recent eGFR and eGFR prior to 3 months ago are both <15 ml/min/1.73m2
Albuminuria 6 Urine microalbumin/creatinine >300 μg/mg on last two consecutive checks at least 24 h apart
Chronic Kidney Disease Progression 7 eGFR drop from ≥90 (CKD stage 1) to <89 ml/min/1.73m2 (CKD stage 2), accompanied by
a 25% drop in eGFR on most recent lab as compared to baseline, with baseline eGFR
defined as the highest eGFR from the past year
8 eGFR drop from 60 to 89 (CKD stage 2) to <59 ml/min/1.73m2 (CKD stage ≥3a), accompanied
by a 25% drop in eGFR on most recent lab as compared to baseline, with baseline eGFR defined
as the highest eGFR from the past year
9 eGFR drop from 45 to 59 (CKD stage 3a) to <45 ml/min/1.73m2 (CKD stage ≥3b), accompanied
by a 25% drop in eGFR on most recent lab as compared to baseline, with baseline eGFR defined
as the highest eGFR from the past year
10 eGFR drop from 30 to 44 (CKD stage 3b) to <30 ml/min/1.73m2 (CKD stage ≥4), accompanied by
a 25% drop in eGFR on most recent lab as compared to baseline, with baseline eGFR defined as
the highest eGFR from the past year
11 eGFR drop from 15 to 29 (CKD stage 4) to <15 ml/min/1.73m2 (CKD stage 5), accompanied by a
25% drop in eGFR on most recent lab as compared to baseline, with baseline eGFR defined as
the highest eGFR from the past year
High Annual GFR Decline 12 Mean eGFR drops ≥5 ml/min/1.73m2 per year, where the current year’s eGFR is defined by the
mean eGFR for the last 365 days and the prior year’s eGFR is defined by the mean eGFR between
366 and 730 days ago
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To put this into perspective, the BWH nephrology
clinic saw 5892 patients in 2013, of which 3326 were
patients who were seen for the first time in 2013. If the
2240 additional patients meeting an indication for refer-
ral had been referred to a nephrologist in 2013, this
would have resulted in a 38.0% (2240/5892) increase in
total nephrology patient volume and 67.3% (2240/3326)
increase in new referral volume.
Given the large number of projected new referrals attrib-
utable to a high annual decline in GFR (scenario 12), we
carried out additional analyses to evaluate the extent to
which this criterion was being met for early versus late
CKD. Among the 1933 patients captured by this rule, 1274
(66%) had a mean eGFR <60 ml/min/1.73m2 in the prior
year while the remaining 659 (34%) patients had a mean
eGFR ≥60 ml/min/1.73m2 in the prior year.
Fig. 1 Comparison of projected referral volume with baseline referral volume in 2013 among patients with CKD meeting a referral indication
Table 3 Comparison of CKD patients meeting an indication for referral who were seen by a nephrologist in 2013 and projected
new referrals
Characteristic All patients with CKD meeting
an indication for referral
Met indication and
seen by nephrologist
Met indication and not seen by
nephrologist (“projected new referral”)
P-value*
No. of patients 2851 611 2240 –
Age in years, mean (SD) 70.2 (12.7) 66.8 (13.8) 71.1 (12.2) < 0.001***

















































Urine microalbumin to creatinine ratio,
μg/mg, median (IQR)
41.5 (IQR [0,233.8]) 133.5 (IQR
[22.2,842.2])
29.1 (IQR [0,108.7]) < 0.001*****
Baseline eGFR is calculated based on the first available creatinine result in 2013
* p-value comparing characteristics for individuals seen and not seen by a nephrologist
** eGFR was not required to define CKD for individuals with persistent albuminuria
*** Welch’s two-sample T-test
**** Χ2 test
***** Wilcoxon rank sum test
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Discussion
This is the first study to examine the feasibility of adher-
ing to the 2012 KDIGO referral recommendations. We
found that 21.4% of all CKD patients meeting an indica-
tion for referral were actually referred to a nephrologist
in 2013. Had the guidelines been followed, we found that
2240 additional patients, almost 4% of our primary care
population, would have been referred to a nephrologist
in 2013. Our finding that only a minority of individuals
were referred upon meeting a referral indication is sup-
ported by data from the Healthy People 2020 initiative,
which showed that only 33% of people were referred to
a nephrologist at least 12 months before the start of
renal replacement therapy in 2012 [5].
KDIGO recognizes that the guidelines may not be pos-
sible to implement in their stated form: “as a global
guideline it is written for use in different health-care set-
tings, but unavoidably its full implementation relies on
health-care resources that are not universally available”
[6]. However, if the guideline is not feasible to imple-
ment at a resource-rich tertiary care center, we question
whether its implementation can be clearly fulfilled in
any setting in the U.S. health care system. The density of
nephrologists is likely to be higher in tertiary care cen-
ters than in community settings, so we would expect
that it would be even less feasible to adhere to the
KDIGO recommendations in community settings where
nephrologists are in short supply.
In the face of limited nephrologist supply, several
strategies may play a role in improving CKD care.
Expanding the nephrology workforce may increase the
capacity to provide specialty care for CKD patients but
the workforce would need to grow by 38% to match the
38% growth in referrals, which is unlikely to be achiev-
able. Another strategy is to optimize the management of
CKD patients in primary care settings using health infor-
mation technology. This may be achieved through com-
puterized clinical decision support delivered at the
point-of-care, delivery of appropriate interventions to a
registry of patients using population health management
software, and streamlining of co-management strategies
between primary care physicians and nephrologist. Un-
derstanding how technology can be used to improve
CKD care is a major focus area for the National Kidney
Disease Education Program [16].
We also need to better understand why primary care
physicians did not refer patients meeting one of the refer-
ral indications. It is possible that the guidelines have not
been widely disseminated among primary care providers
despite their being part of the target audience [6]. Prior
surveys have shown that primary care providers and in-
ternal medicine trainees are unaware of both the presence
and content of guidelines focused on CKD care [17–19].
It is also possible that primary care providers disagree with
the guidelines for patients they decided not to refer. We
found that projected new referrals were older than
patients who were actually referred. Primary care physi-
cians may have perceived this group to be inappropriate
candidates for dialysis and thus opted not to refer them to
a nephrologist.
One potential limitation is our translation of the guide-
lines to computable criteria and the exclusion of referral
guidelines which are difficult to implement via computa-
tional techniques (e.g., hereditary kidney disease), which
would mean that our estimate of new referrals is low. Our
analysis is limited by its focus on a single tertiary care cen-
ter’s affiliated primary care practices, which may be biased
by local referral patterns. However, the BWH primary care
population is diverse and drawn from a wide catchment
area. We may have underestimated nephrology referrals
due mischaracterization of provider specialty in the billing
data or due to referrals by primary care providers to ne-
phrologists outside our network; however, we randomly
selected and reviewed 20 charts and did not find mischar-
acterization of provider specialty.
Conclusions
The main implication of our findings is that adhering to the
KDIGO referral recommendations may not be feasible. We
need to consider new strategies on how to deliver optimal
care to CKD patients using the available workforce in the
U.S. health care system.
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